News Article

Dr Michelle Tempest and Dr Karen Sayal reveal in this July 2019 Laing Buisson article promising opportunities investing in immuno therapy treatments

Cancer therapeutic landscape is shifting to more distinct and personalised immunotherapy treatments.

With a market expected to almost triple by 2025, several biotech firms are in early clinical trials.

Opportunities arise in

– novel combinations of check-point inhibitors: engineered proteins that bind to cancer cells and indirectly signal an ‘auto-destruct’ response from the immune system

– cellular based immunotherapy that involves, for part, re-infusing specific expanded immune cells (ACT, adoptive cell transfer)

Challenges remain because of the toxicity risk and the high costs associated.